SecBot SecBot
8-K ·Filed Nov 10, 2026

TTRX

Turn Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 16h ago SEC0001213900-26-117781
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for Phase 2 topline results for GX-03 in AD expected Q1 2027, which is a key catalyst. The company's cash runway extends only into Q3 2027, so watch for potential capital raises or partnership announcements to fund later-stage trials.

DirectionNeutral
Confidencehigh
Horizonmonths

GX-03

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
Next catalyst
None dated

What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$9.92
T+0 close · Nov 10, 2026 · via day close
Latest settled
+6.55%
T+1 · $10.57
Vs SPY
+5.23%
α at T+1
Next horizon
T+5
in 6h
  1. T+0 · Nov 10 $9.92entry
  2. T+1 · 6d ago +6.55%α +5.23% · $10.57
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Turn Therapeutics released an updated investor presentation on November 10, 2026, detailing progress across its pipeline, including Phase 2a/2b data for GX-03 in atopic dermatitis (AD) with topline results expected Q1 2027, and plans for Phase 3 initiation in onychomycosis and Phase 2a initiation in hidradenitis suppurativa. The filing also disclosed a cash balance of $10.4M as of September 30, 2026, with runway into Q3 2027, and noted the need for additional capital to fund certain milestones.

Key Facts

  • Cash balance of $10.4M as of September 30, 2026
  • Cash runway into Q3 2027
  • ~30.5M common shares outstanding as of September 30, 2026
  • Phase 2a/2b trial for GX-03 in moderate-to-severe AD ongoing, topline results expected Q1 2027
  • Phase 3 initiation for onychomycosis planned for Q2 2027
  • Phase 2a initiation for hidradenitis suppurativa planned for Q1 2027
  • 200,000+ patients have received GX-03 with zero reported adverse events
  • GX-03 has been FDA cleared as non-cytotoxic, non-sensitizing and non-irritating
  • 17 issued patents with coverage through 2040
  • ~$33M total money raised since inception (2015)
  • ~$24M cash burned since inception
  • ~$1M/quarter current G&A burn as a public company
  • Additional capital available under existing facilities
  • Cash runway funded milestone requires additional capital for certain pipeline events

Financial Impact

Cash balance of $10.4M provides runway into Q3 2027; additional capital needed for certain pipeline milestones

cashdilution

Risk Factors

  • Cash runway only into Q3 2027; additional capital required for certain pipeline milestones
  • Clinical trial risks for GX-03 in AD, onychomycosis, and HS
  • Reliance on third-party partnerships and manufacturers
  • No guarantees that pipeline products will prove commercially successful
  • Regulatory challenges and uncertainties in clinical development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-117781
Document: ea0311587-8k_turn.htm0001213900-26-117781
Document: 0001213900-26-117781-index-headers.html0001213900-26-117781
Document: 0001213900-26-117781-index.html0001213900-26-117781
Document: 0001213900-26-117781.txt0001213900-26-117781

Track record

19 reports on TTRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $9.92 Now $8.55 −13.81% settles Feb 8
  3. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  4. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  5. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $9.79 Now $8.55 −12.67% settles Feb 5
  6. Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
  7. Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
  8. Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
  9. Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
  10. Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026